Centessa Pharmaceuticals PLC ADR Total Liabilities
Centessa Pharmaceuticals PLC ADR total liabilities. Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has total liabilities worth $154.41 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Centessa Pharmaceuticals PLC ADR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Centessa Pharmaceuticals PLC ADR (2019–2025)
Total liabilities of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. This chart illustrates how Centessa Pharmaceuticals PLC ADR's total liabilities have evolved over time, based on quarterly financial data. Explore CNTA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Centessa Pharmaceuticals PLC ADR Competitors by Total Liabilities
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
China | CN¥19.26 Billion |
|
Mango Excellent Media Co Ltd
SHE:300413
|
China | CN¥9.74 Billion |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
China | CN¥23.89 Billion |
|
Weichai Power Co. Ltd
F:WI4
|
Germany | €245.16 Billion |
|
Nice Ltd ADR
NASDAQ:NICE
|
USA | $1.31 Billion |
|
Matador Resources Company
NYSE:MTDR
|
USA | $7.24 Billion |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
USA | $1.87 Billion |
|
First International Bank of Israel Ltd
TA:FIBI
|
Israel | ILA278.42 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Centessa Pharmaceuticals PLC ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Centessa Pharmaceuticals PLC ADR assets under control.
Liquidity & Leverage Metrics
Centessa Pharmaceuticals PLC ADR Total Liabilities Ratios Explained
Centessa Pharmaceuticals PLC ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Centessa Pharmaceuticals PLC ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual total liabilities of Centessa Pharmaceuticals PLC ADR from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $160.63 Million | -8.34% |
| 2024-12-31 | $175.25 Million | +41.33% |
| 2023-12-31 | $124.00 Million | +14.67% |
| 2022-12-31 | $108.14 Million | -21.69% |
| 2021-12-31 | $138.08 Million | +1502.05% |
| 2020-12-31 | $8.62 Million | +42.09% |
| 2019-12-31 | $6.07 Million | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more